Delving into the Latest Updates on TBI-302(Therapure Biopharma, Inc.) with Synapse

Overview

Basic Info

Drug Type

Drug conjugates

Synonyms

Haemoglobin-conjugated floxuridine

+ [1]

Target

TYMS

Mechanism

TYMS inhibitors(Thymidylate synthase inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Colorectal CancerHepatocellular CarcinomaLiver Cancer+ [1]

Originator Organization

Therapure Biopharma, Inc.

Active Organization-

Inactive Organization

Therapure Innovations

Therapure Biopharma, Inc.

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

Seventy-four patients with liver metastasis from proved colorectal primary adenocarcinoma were entered into a prospective, randomized clinical trial to evaluate treatment with intra-arterial floxuridine compared with standard outpatient therapy with fluorouracil delivered by intravenous bolus injection. Eligible patients were randomized to hepatic arterial chemotherapy with an implanted infusion pump or systemic chemotherapy. No crossover between treatment arms was permitted, and patients were followed up to progression and death. Objective tumor response was observed in 48% of patients receiving intra-arterial floxuridine and in 21% of patients receiving intravenous fluorouracil. Time to hepatic progression was significantly longer in the group given intra-arterial therapy: 15.7 vs 6.0 months. However, time to overall progression (6.0 vs 5.0 months) and survival (12.6 vs 10.5 months) were not statistically different. Based on these data, we cannot recommend treatment with intra-arterial floxuridine as given in this study for metastatic colorectal cancer to the liver.

100 Deals associated with TBI-302(Therapure Biopharma, Inc.)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Liver Cancer	Phase 1	US	Therapure Innovations	24 Aug 2020
Hepatocellular Carcinoma	Phase 1	US	Therapure Biopharma, Inc.	01 Dec 2019
Pancreatic carcinoma non-resectable	Phase 1	US	Therapure Biopharma, Inc.	01 Dec 2019
Colorectal Cancer	Phase 1	CA	Therapure Innovations	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AACR2016	Phase 1	Liver Cancer Second line	-	TBI 302	vjasqicplo(ndwbqhzljl) = mjdzrdbvue kkxkoyafpu (mwtbghmrlr )	-	15 Jul 2016
				Saline	vjasqicplo(ndwbqhzljl) = dafzfvwetm kkxkoyafpu (mwtbghmrlr )